Cordant Inc’s Medifast MED Stock Holding History

Cordant Inc’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4	Closed	-$1K	–	774
2022 Q1	$1K	Buy	+4	New	+$754	﹤0.01%	1011

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.46B AUM 71.13% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Cordant Inc's MED Position: Q2 2022 in Review

Cordant Inc sold out of Medifast (MED) in Q2 2022, closing a stake of 4 shares — an estimated $1K sold.

Cordant Inc first reported a position in MED in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 284 funds tracked by Wall St. Rank hold MED as of Q2 2022.

Cordant Inc reported no remaining Medifast position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 4 Medifast shares in Q2 2022, an estimated $1K.
Cordant Inc first reported a position in Medifast in Q1 2022 and held it in 1 quarter.
Cordant Inc's Medifast position peaked at $1K in Q1 2022.
284 funds tracked by Wall St. Rank held Medifast as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.